Russell Investments Group Ltd. Sells 16,752 Shares of Biohaven Ltd. (NYSE:BHVN)

Russell Investments Group Ltd. decreased its position in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 10.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 146,125 shares of the company's stock after selling 16,752 shares during the quarter. Russell Investments Group Ltd. owned about 0.14% of Biohaven worth $5,458,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the company. Teacher Retirement System of Texas raised its stake in shares of Biohaven by 31.6% during the 4th quarter. Teacher Retirement System of Texas now owns 23,320 shares of the company's stock worth $871,000 after purchasing an additional 5,600 shares during the period. Bank of New York Mellon Corp grew its stake in Biohaven by 9.1% during the fourth quarter. Bank of New York Mellon Corp now owns 295,078 shares of the company's stock valued at $11,021,000 after acquiring an additional 24,703 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Biohaven by 85.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company's stock worth $40,448,000 after acquiring an additional 372,737 shares during the period. American Century Companies Inc. lifted its stake in Biohaven by 9.5% in the 4th quarter. American Century Companies Inc. now owns 558,761 shares of the company's stock worth $20,870,000 after purchasing an additional 48,286 shares in the last quarter. Finally, Alliancebernstein L.P. grew its position in shares of Biohaven by 6.6% during the 4th quarter. Alliancebernstein L.P. now owns 96,236 shares of the company's stock valued at $3,594,000 after purchasing an additional 5,951 shares in the last quarter. Institutional investors own 88.78% of the company's stock.

Insider Transactions at Biohaven

In other news, Director John W. Childs acquired 32,700 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average cost of $30.47 per share, with a total value of $996,369.00. Following the acquisition, the director now directly owns 2,320,571 shares of the company's stock, valued at approximately $70,707,798.37. The trade was a 1.43 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 16.00% of the company's stock.

Biohaven Trading Up 9.2 %

NYSE:BHVN traded up $1.73 during mid-day trading on Friday, reaching $20.41. The company's stock had a trading volume of 2,098,008 shares, compared to its average volume of 1,120,290. The firm's fifty day moving average price is $28.88 and its two-hundred day moving average price is $38.78. The stock has a market cap of $2.08 billion, a P/E ratio of -2.18 and a beta of 1.33. Biohaven Ltd. has a 12-month low of $15.79 and a 12-month high of $55.70.

Biohaven (NYSE:BHVN - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.29). Analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BHVN has been the topic of a number of research analyst reports. JPMorgan Chase & Co. decreased their target price on Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. Royal Bank of Canada reissued an "outperform" rating and issued a $61.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft set a $60.00 target price on Biohaven and gave the company a "buy" rating in a research note on Thursday, March 20th. Morgan Stanley reduced their price objective on Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $54.00 target price on shares of Biohaven in a research note on Tuesday, March 4th. Fourteen analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $62.77.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.